SOURCE: Gene Express, Inc.

June 12, 2008 09:00 ET

Gene Express Appoints Michael Rowe to Senior VP of Global Marketing

TOLEDO, OH--(Marketwire - June 12, 2008) - Gene Express, Inc. today announced the appointment of Michael M. Rowe, to Senior Vice President of Global Marketing.

Gerald Vardzel, CEO of Gene Express, commented, "We are pleased to have Michael join our team. Michael will be responsible for the execution of Gene Express' global marketing campaign and strategy. With his 25 years of experience in pharmaceuticals, biologics and devices and track record of success, he will be invaluable for the Company."

"Gene Express offers its partners and customers genetic diagnostics and standards that will bring forward the promise of personalized medicine. I am excited about being part of this new frontier in healthcare," said Michael Rowe.

Prior to joining Gene Express, Michael Rowe held numerous positions in US and global marketing and research for the pharmaceutical and biotechnology industries. Most recently, he served as Senior Director of U.S. Therapeutics Marketing at Bayer, where he worked as the marketing head for the biologic, Betaseron.

Prior to Mr. Rowe's senior marketing positions at Bayer, he served as the Director of Cardiovascular Marketing at Women First Healthcare; Senior Marketing Manager at Pfizer for Lipitor; Director of Global Outcomes Research and Strategic Marketing Research at Allergan; and Manager of International Marketing and Marketing Research at Warner-Lambert Company.

Mr. Rowe holds a Master of Science from Rensselaer Polytechnic Institute, and a Bachelor of Arts from the State University of New York at Stony Brook. He has been an invited speaker at a number of marketing conferences, has appeared in pharmaceutical marketing publications and has served as a consultant to both pharmaceutical companies and advertising agencies.

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information